Prescription Drugs Market Research Reports & Industry Analysis
The prescription drugs industry is a key cornerstone of healthcare, delivering vital medications that improve and save lives. As this industry continues to evolve, understanding its nuances can be an ongoing challenge. MarketResearch.com provides hundreds of authoritative prescription drugs market research reports to help stakeholders understand the shifting market landscape and devise effective business strategies.
The Latest Prescription Drugs Market Analysis
- We provide data-packed reports on a wide range of product types, therapeutic areas, regions, and companies.
- Our research includes in-depth analyses of prescription drug market size, growth forecasts, and drivers and challenges.
- In addition, we cover the rise of personalized medicine and gene therapies, as well as regulatory issues and pricing models.
Your Dedicated Research Partner
As the prescription drugs industry shifts and changes, MarketResearch.com equips you with the tools to thrive. Trusted for decades as a reliable research partner, our clients include top pharmaceutical companies, investment banks, and universities. Whether you are exploring new markets or seeking to futureproof your business, our prescription drugs industry research reports offer a wealth of knowledge to inform your strategy. Get started by exploring our vast selection of reports on the prescription drugs industry today.
Prescription Drugs Industry Research & Market Reports
-
Opioids
... 2.3% over the analysis period 2024-2030. Extended-Release / Long-Acting Opioids, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$18.7 Billion by the end of the analysis ... Read More
-
Swine Health
... CAGR of 5.8% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$2.5 Billion by the end of the analysis period. ... Read More
-
Spinal Cord Trauma Treatment
... 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$1.7 Billion by the end ... Read More
-
Herpes Zoster Treatment
... at a CAGR of 1.9% over the analysis period 2024-2030. Antiviral Medications, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$134.0 Million by the end of ... Read More
-
Dysphagia Management
... CAGR of 4.8% over the analysis period 2024-2030. Nutritional Solutions, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$4.7 Billion by the end of the analysis ... Read More
-
Emergency Contraceptive Pills
... at a CAGR of 2.4% over the analysis period 2024-2030. Combination Pills, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$484.2 Million by the end of ... Read More
-
Antivenoms
... 7.4% over the analysis period 2024-2030. Snakes Species, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth ... Read More
-
Benign Prostatic Hyperplasia (BPH) Drugs
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Alpha-Blockers, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.4 Billion by ... Read More
-
Cold Pain Therapy
... at a CAGR of 4.3% over the analysis period 2024-2030. OTC Products, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Antipsychotic Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$15.7 Billion by the end of ... Read More
-
Constipation Treatment
... CAGR of 5.9% over the analysis period 2024-2030. Laxatives, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$12.3 Billion by the end of the analysis period. ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the ... Read More
-
Motion Sickness Treatment
... at a CAGR of 2.0% over the analysis period 2024-2030. Anticholinergic Treatment, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$532.7 Million by the end of ... Read More
-
Hepatitis C Treatment
... at a CAGR of 10.7% over the analysis period 2024-2030. HCV Protease Inhibitors, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$25.3 Billion by the end ... Read More
-
Potassium Bromide
... CAGR of 4.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.5 Million While China is Forecast to Grow at 7.8% CAGR The Potassium Bromide market in the U.S. is estimated at ... Read More
-
Stroke Management
... CAGR of 5.3% over the analysis period 2024-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$35.9 Billion by the end of the analysis ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis Application, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end ... Read More
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Immune Checkpoint Inhibitors
... at a CAGR of 16.5% over the analysis period 2024-2030. PD-1, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$109.0 Billion by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Antineoplastic Agents
... CAGR of 7.3% over the analysis period 2024-2030. Chemotherapeutic Agents Application, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$137.9 Billion by the end of the ... Read More
-
Genitourinary Drugs
... CAGR of 2.3% over the analysis period 2024-2030. Urologicals, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Cryptococcosis Treatment
... CAGR of 4.5% over the analysis period 2024-2030. Amphotericin B Treatment, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$5.5 Billion by the end of the ... Read More
-
Influenza Medication
... CAGR of 1.9% over the analysis period 2024-2030. Zanamivir, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$123.9 Million by the end of the analysis period. ... Read More
Research Assistance
